RAS mutation status predicts activity of the SHP2 inhibitor TNO155 in RAS-pathway driven fusion-negative rhabdomyosarcoma

被引：0
|
作者：
Baker, Andrew
Odeniyide, Patience
Skaist, Alyza
Lisok, Alla
Fertig, Elana
Wang, Jiawan
Pratilas, Christine
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-A096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A096
引用
收藏
页数：2
相关论文
共 2 条
  • [1] NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma
    Valencia-Sama, Ivette
    Ladumor, Yagnesh
    Kee, Lynn
    Adderley, Teresa
    Christopher, Gabriella
    Robinson, Claire M.
    Kano, Yoshihito
    Ohh, Michael
    Irwin, Meredith S.
    CANCER RESEARCH, 2020, 80 (16) : 3413 - 3423
  • [2] ERAS-601, a potent allosteric inhibitor of SHP2, demonstrates anti-tumor activity in RAS/MAPK-driven tumor models
    Martin, Leenus
    Patel, Roopal
    Zhang, Jingchuan
    Yang, Jennifer
    Nevarez, Robin
    Congdon, Taylor
    Brail, Les
    Shoemaker, Robert
    CANCER RESEARCH, 2022, 82 (12)
1